Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Sells 6,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tina Marriott also recently made the following trade(s):

• On Thursday, September 26th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.00, for a total value of $42,000.00.
• On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.56, for a total value of $45,360.00.

Recursion Pharmaceuticals Stock Down 1.9 %

Recursion Pharmaceuticals stock opened at $6.74 on Wednesday. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -4.16 and a beta of 0.80. The stock has a fifty day simple moving average of $6.70 and a two-hundred day simple moving average of $7.67. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business’s quarterly revenue was up 30.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.38) earnings per share. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on RXRX. Jefferies Financial Group reduced their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. KeyCorp reduced their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.40.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 14.5% in the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after buying an additional 3,555,357 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after buying an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after buying an additional 349,554 shares during the last quarter. Kinnevik AB publ boosted its stake in shares of Recursion Pharmaceuticals by 14.4% in the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after buying an additional 1,500,000 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its position in Recursion Pharmaceuticals by 12.6% during the first quarter. Nikko Asset Management Americas Inc. now owns 10,362,803 shares of the company’s stock valued at $103,110,000 after purchasing an additional 1,159,023 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.